2024 | Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
| FUTURE ONCOLOGY |
2024 | NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
| CANCER DISCOVERY |
2024 | ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial | CLINICAL CANCER RESEARCH |
2024 | Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3 | JOURNAL OF THORACIC ONCOLOGY |
2024 | Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
| ESMO OPEN |
2024 | Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
| BMC MEDICINE |
2024 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2024 | Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
| ONCOLOGIST |
2024 | Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation | LUNG CANCER |
2024 | Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
2024 | Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
| Lung Cancer : targets and therapy |
2024 | BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2024 | Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA | ANNALS OF ONCOLOGY |
2024 | Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2024 | D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
| CANCER DISCOVERY |
2024 | Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities | LUNG CANCER |
2024 | Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer | CLINICAL CANCER RESEARCH |
2024 | A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study | Cancer Treatment and Research Communications |
2024 | Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
| CANCER RESEARCH COMMUNICATIONS |
2024 | Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
| BMC CANCER |
2024 | Novel allosteric glutaminase inhibitors with macrocyclic structure activity relationship analysis (part 2) | BULLETIN OF THE KOREAN CHEMICAL SOCIETY |
2024 | ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). | JOURNAL OF CLINICAL ONCOLOGY |
2024 | A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
| ONCOIMMUNOLOGY |
2024 | Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2024 | A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study
| CLINICAL LUNG CANCER |
2024 | Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK |
2024 | Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103) | JOURNAL OF CLINICAL PHARMACOLOGY |
2024 | Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
| CANCER MEDICINE |
2024 | Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC | CLINICAL CANCER RESEARCH |
2024 | Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations | LUNG CANCER |
2024 | Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
| LUNG CANCER |
2024 | Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types
| FRONTIERS IN IMMUNOLOGY |
2024 | Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
| LUNG CANCER |
2024 | Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC | JOURNAL OF THORACIC ONCOLOGY |
2024 | Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
| JTO Clinical and Research Reports |
2024 | CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production
| FRONTIERS IN IMMUNOLOGY |
2024 | Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C | ANNALS OF ONCOLOGY |
2024 | Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
| NATURE |
2024 | Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial | LUNG CANCER |
2024 | Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report
| JTO Clinical and Research Reports |
2024 | Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing
| PLOS ONE |
2024 | Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
| LUNG CANCER |
2024 | Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial | JOURNAL OF CLINICAL ONCOLOGY |
2024 | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
| ANNALS OF ONCOLOGY |
2024 | Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
| CANCER RESEARCH AND TREATMENT |
2024 | Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial | JOURNAL OF CLINICAL ONCOLOGY |
2024 | Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2024 | Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
| ORAL ONCOLOGY |
2024 | Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2024 | Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study | THYROID |